Literature DB >> 8603760

Characterization of human DNA topoisomerase II as an autoantigen recognized by patients with IDDM.

Y H Chang1, J Hwang, H F Shang, S T Tsai.   

Abstract

Autoantibodies against several cytoplasmic autoantigens such as glutamic acid decarboxylase, heat shock protein 65, insulin, and carboxypeptidase H have been identified in the sera of patients with IDDM. To investigate whether type II DNA topoisomerase (TopII) is an autoantigen in IDDM patients, we have constructed a series of overlapping DNA TopII fragments that covered the entire length of this enzyme. These fragments were used as antigens to screen sera of IDDM patients. We have examined 195 Chinese IDDM patients (mean age 14.2 +/- 7.5 years, age at onset 9.2 +/- 6.4 years, duration of diabetes 4.6 +/- 3.4 years) and 51 nondiabetic individuals. The results showed that DNA TopII autoantibodies were detected in 49.2 and 47.2% of IDDM patients using purified TopII fragments and full-length TopII as antigens, respectively. The frequency of anti-TopII positivity was relatively stable irrespective of sex and disease duration. The patients were slightly older at onset and the prevalence of anti-thyroglobulin/anti-microsomal autoantibodies was twice that in the IDDM subgroup positive for anti-TopII than in IDDM patients who were negative for anti-TopII. We also characterized the epitopes of DNA TopII that were recognized by IDDM sera. Those epitopes resided mostly in three distinct domains. One resided in amino acid residues 1-147, another in amino acid residues 286-472, and the third in the COOH-terminal one-third of DNA TopII. Intriguingly, we found that these epitopes shared similarity (up to 36% identity and 63.6% homology) to previously identified epitopes of IDDM autoantigens.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8603760     DOI: 10.2337/diab.45.4.408

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  7 in total

1.  Anti-topoisomerase II alpha autoantibodies in systemic sclerosis-association with pulmonary hypertension and HLA-B35.

Authors:  B Grigolo; I Mazzetti; R Meliconi; S Bazzi; R Scorza; M Candela; A Gabrielli; A Facchini
Journal:  Clin Exp Immunol       Date:  2000-09       Impact factor: 4.330

2.  An update on the use of NOD mice to study autoimmune (Type 1) diabetes.

Authors:  Rodolfo José Chaparro; Teresa P Dilorenzo
Journal:  Expert Rev Clin Immunol       Date:  2010-11       Impact factor: 4.473

Review 3.  Novel biomarkers in type 1 diabetes.

Authors:  Yulan Jin; Jin-Xiong She
Journal:  Rev Diabet Stud       Date:  2012-12-28

4.  Mapping of topoisomerase II alpha epitopes recognized by autoantibodies in idiopathic pulmonary fibrosis.

Authors:  B Grigolo; I Mazzetti; R M Borzì; I D Hickson; M Fabbri; L Fasano; R Meliconi; A Facchini
Journal:  Clin Exp Immunol       Date:  1998-12       Impact factor: 4.330

Review 5.  Pharmacological approaches to the prevention of autoimmune diabetes.

Authors:  W E Winter; D V House; D Schatz
Journal:  Drugs       Date:  1997-06       Impact factor: 9.546

6.  Proteinase 3 and dihydrolipoamide dehydrogenase (E3) are major autoantigens in hepatitis C virus (HCV) infection.

Authors:  Y-Y Wu; T-C Hsu; T-Y Chen; T-C Liu; G-Y Liu; Y-J Lee; G J Tsay
Journal:  Clin Exp Immunol       Date:  2002-05       Impact factor: 4.330

Review 7.  Broken by the Cut: A Journey into the Role of Topoisomerase II in DNA Fragility.

Authors:  Naomi D Atkin; Heather M Raimer; Yuh-Hwa Wang
Journal:  Genes (Basel)       Date:  2019-10-12       Impact factor: 4.141

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.